TMCI · Treace Medical Concepts, Inc.
$4.56
+0.11 (+2.47%)
At close · Aug 19
Market Cap
$289.40M
Shares
65.03M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.56
Open$4.46
Day$4.37–4.62
52W close$1.20–7.70
Avg vol 30d421K
Short int1.7M · 2.6% float · 5.5d
Short vol26%
Last earningsAug 7, 2026
DataApr 2021–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+56%
above
Price vs 50-day avg
+5%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
52%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
+117%
trailing
YTD return
+86%
this year
Relative strength
+106%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +31 funds added
Insider flow
Accumulating
Net +$617.7K over 90 days · 0% sells
Short interest
Falling
2.61% of float · ▼ -7.9% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
117 holders — near 3-yr low, contrarian setup
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
80%
contracting
EPS growth
−3%
Y/Y
Free cash flow
$-29.5M
Balance sheet
$46.7M
net debt
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 7, 2026
Revenue
· full-year 2026
Initiated
$204M – $212M
prior FY $212.69M
midpoint −2.2% Y/Y
Reduction in cash usage
· full-year 2026
Initiated
up to 50%
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Revenue
· full-year 2025
$211M – $213M
Reduction in cash used
· full-year 2025
43% – 47%
Guided vs delivered
· last 3 settled
Revenue
full-year 2025
guided $211M – $213M
$212.69M
In line
Revenue
full year 2024
guided $220M – $225M
$209.36M
Miss −5.9%
Revenue
full year 2023
guided $182M – $186M
$187.12M
Beat +1.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+56%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
52%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +31 funds added
Insider flow
Accumulating
Net +$617.7K over 90 days · 0% sells
Short interest
Falling
2.61% of float · ▼ -7.9% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
117 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $5 · 52%
Range high $8
vs 200-day avg +56%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | -$3.5M | the second quarter 2026 | — |
|
|
|||
| Active surgeons | 3,337 | full-year 2025 | — |
| Granted patents | 135 | full-year 2025 | — |
| Net new active surgeons | 202 | full-year 2025 | — |
| Pending patent applications | 199 | full-year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TMCI
this stock
Treace Medical Concepts, Inc.
|
$289.40M | +86.1% | +1.6% | — | 2.6% |
|
ABT
Abbott Laboratories
|
$196.27B | -8.7% | +5.7% | 31.6 | 1.3% |
|
SYK
Stryker Corp
|
$127.34B | -3.3% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -2.0% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -45.5% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TMCI | -4.0% | +14.9% | +117.1% | +5.8% | +86.1% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -3.6% | +12.0% | +105.6% | +2.9% | +73.3% |